LivaNova (NASDAQ:LIVN) Rating Lowered to “Buy” at StockNews.com

LivaNova (NASDAQ:LIVN) was downgraded by StockNews.com from a “strong-buy” rating to a “buy” rating in a research note issued on Saturday.

Other analysts also recently issued research reports about the stock. The Goldman Sachs Group started coverage on shares of LivaNova in a report on Friday, October 4th. They set a “buy” rating and a $65.00 target price for the company. Mizuho reduced their price objective on LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a report on Thursday, October 31st. Robert W. Baird upped their target price on LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. Baird R W raised LivaNova from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 17th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $75.00 price objective on shares of LivaNova in a report on Tuesday, November 12th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $69.17.

LivaNova Trading Down 0.4 %

LIVN stock opened at $52.10 on Friday. LivaNova has a one year low of $42.75 and a one year high of $64.47. The stock has a market cap of $2.83 billion, a price-to-earnings ratio of 124.05 and a beta of 1.01. The company has a fifty day moving average price of $51.77 and a two-hundred day moving average price of $52.93. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87.

Hedge Funds Weigh In On LivaNova

A number of hedge funds have recently added to or reduced their stakes in LIVN. Hexagon Capital Partners LLC grew its holdings in shares of LivaNova by 117.8% during the 2nd quarter. Hexagon Capital Partners LLC now owns 684 shares of the company’s stock worth $37,000 after purchasing an additional 370 shares in the last quarter. Fifth Third Bancorp grew its stake in LivaNova by 97.1% during the second quarter. Fifth Third Bancorp now owns 674 shares of the company’s stock worth $37,000 after buying an additional 332 shares in the last quarter. Lazard Asset Management LLC bought a new position in LivaNova in the 1st quarter valued at about $84,000. Canada Pension Plan Investment Board acquired a new position in shares of LivaNova in the 2nd quarter valued at approximately $88,000. Finally, Acadian Asset Management LLC acquired a new position in shares of LivaNova in the 1st quarter valued at approximately $94,000. Institutional investors own 97.64% of the company’s stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.